Hello_老虎社区_美港股上老虎

MonkeyApe
2021-10-19

Hello

Entasis Therapeutics soared over 26% in premarket trading

Entasis Therapeutics Holdings Inc. says primary endpoint met in late-stage trial for SUL-DUR in Acin

Entasis Therapeutics soared over 26% in premarket trading

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":850755919,"tweetId":"850755919","gmtCreate":1634631345575,"gmtModify":1634631345575,"author":{"id":3579074574585533,"idStr":"3579074574585533","authorId":3579074574585533,"authorIdStr":"3579074574585533","name":"MonkeyApe","avatar":"https://static.tigerbbs.com/3ccc6d2e6557cc9da952abf531f639ec","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":37,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Hello</p></body></html>","htmlText":"<html><head></head><body><p>Hello</p></body></html>","text":"Hello","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/850755919","repostId":1186895664,"repostType":4,"repost":{"id":"1186895664","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634630908,"share":"https://www.laohu8.com/m/news/1186895664?lang=&edition=full","pubTime":"2021-10-19 16:08","market":"us","language":"en","title":"Entasis Therapeutics soared over 26% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1186895664","media":"Tiger Newspress","summary":"Entasis Therapeutics Holdings Inc. says primary endpoint met in late-stage trial for SUL-DUR in Acin","content":"<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> says primary endpoint met in late-stage trial for SUL-DUR in Acinetobacter infections.</p>\n<p><img src=\"https://static.tigerbbs.com/6dfdb354decf318b731b62985eaf45b8\" tg-width=\"981\" tg-height=\"559\" referrerpolicy=\"no-referrer\"></p>\n<p>Announcing topline results from a Phase 3 registrational trial for SUL-DUR, Entasis Therapeutics(NASDAQ:ETTX)says that the 207-patient study met the primary endpoint for patients withcarbapenem-resistant<i>Acinetobacter</i>infections.</p>\n<p>Entasis (ETTX) have&nbsp;added ~26.7%in the pre-market.</p>\n<p>On the tolerability front, the two-part study reached the primary safety objective showing a decline in nephrotoxicity with statistical significance.</p>\n<p>In the CRABC m-MITT population (n=125) of Part A of the study, 28-day all-cause mortality stood at 19.0% (12/63) compared to 32.3% (20/62) in the colistin arm, indicating the achievement of the primary endpoint with statistical non-inferiority versus colistin.</p>\n<p>The clinical cure at Test of Cure (TOC) reached 61.9% in the SUL-DUR arm compared to 40.3% in the colistin arm showing statistical significance.</p>\n<p>~88% of patients who received SUL-DUR experienced adverse events (AEs) versus ~94% and ~89% in the colistin arms Part A and B, respectively, showing a comparable safety profile for the experimental therapy.</p>\n<p>“We look forward to discussing our data with the regulatory agencies and preparing our first regulatory submission in mid-2022,” CEO Manos Perros remarked.</p>\n<p>Interested in real-time updates on the biggest gainers and losers in the market today? Take a look at Seeking&nbsp;Alpha's Stocks on the Move.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Entasis Therapeutics soared over 26% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEntasis Therapeutics soared over 26% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-19 16:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> says primary endpoint met in late-stage trial for SUL-DUR in Acinetobacter infections.</p>\n<p><img src=\"https://static.tigerbbs.com/6dfdb354decf318b731b62985eaf45b8\" tg-width=\"981\" tg-height=\"559\" referrerpolicy=\"no-referrer\"></p>\n<p>Announcing topline results from a Phase 3 registrational trial for SUL-DUR, Entasis Therapeutics(NASDAQ:ETTX)says that the 207-patient study met the primary endpoint for patients withcarbapenem-resistant<i>Acinetobacter</i>infections.</p>\n<p>Entasis (ETTX) have&nbsp;added ~26.7%in the pre-market.</p>\n<p>On the tolerability front, the two-part study reached the primary safety objective showing a decline in nephrotoxicity with statistical significance.</p>\n<p>In the CRABC m-MITT population (n=125) of Part A of the study, 28-day all-cause mortality stood at 19.0% (12/63) compared to 32.3% (20/62) in the colistin arm, indicating the achievement of the primary endpoint with statistical non-inferiority versus colistin.</p>\n<p>The clinical cure at Test of Cure (TOC) reached 61.9% in the SUL-DUR arm compared to 40.3% in the colistin arm showing statistical significance.</p>\n<p>~88% of patients who received SUL-DUR experienced adverse events (AEs) versus ~94% and ~89% in the colistin arms Part A and B, respectively, showing a comparable safety profile for the experimental therapy.</p>\n<p>“We look forward to discussing our data with the regulatory agencies and preparing our first regulatory submission in mid-2022,” CEO Manos Perros remarked.</p>\n<p>Interested in real-time updates on the biggest gainers and losers in the market today? Take a look at Seeking&nbsp;Alpha's Stocks on the Move.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ETTX":"Entasis Therapeutics Holdings Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186895664","content_text":"Entasis Therapeutics Holdings Inc. says primary endpoint met in late-stage trial for SUL-DUR in Acinetobacter infections.\n\nAnnouncing topline results from a Phase 3 registrational trial for SUL-DUR, Entasis Therapeutics(NASDAQ:ETTX)says that the 207-patient study met the primary endpoint for patients withcarbapenem-resistantAcinetobacterinfections.\nEntasis (ETTX) have added ~26.7%in the pre-market.\nOn the tolerability front, the two-part study reached the primary safety objective showing a decline in nephrotoxicity with statistical significance.\nIn the CRABC m-MITT population (n=125) of Part A of the study, 28-day all-cause mortality stood at 19.0% (12/63) compared to 32.3% (20/62) in the colistin arm, indicating the achievement of the primary endpoint with statistical non-inferiority versus colistin.\nThe clinical cure at Test of Cure (TOC) reached 61.9% in the SUL-DUR arm compared to 40.3% in the colistin arm showing statistical significance.\n~88% of patients who received SUL-DUR experienced adverse events (AEs) versus ~94% and ~89% in the colistin arms Part A and B, respectively, showing a comparable safety profile for the experimental therapy.\n“We look forward to discussing our data with the regulatory agencies and preparing our first regulatory submission in mid-2022,” CEO Manos Perros remarked.\nInterested in real-time updates on the biggest gainers and losers in the market today? Take a look at Seeking Alpha's Stocks on the Move.","news_type":1,"symbols_score_info":{"ETTX":0.9}},"isVote":1,"tweetType":1,"viewCount":2741,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":5,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Entasis Therapeutics soared over 26% in premarket trading

评论（1）

热议股票